Table 2 Reactogenicity of COVID-19 vaccines approved by WHO for emergency use.
From: Use of analgesics/antipyretics in the management of symptoms associated with COVID-19 vaccination
Vaccine | Trial/population | Reactogenicity | |
|---|---|---|---|
Injection-site pain | Selected systemic symptoms | ||
mRNA-based | |||
BNT162b2 (Pfizer/BioNTech)37 | Phase 2/3, OB, PC, R N = 18,556 (n = 8,183 reactogenicity subset) Age: ≥16 years (median 52 years, range 16–91 years) Males: 51% | Dose 1: 83% (≤55 years); 71% (>55 years) Dose 2: 71% (≤55 years); 66% (>55 years) | Fatigue Dose 1: 47% (≤55 years); 34% (>55 years) Dose 2: 59% (≤55 years); 51% (>55 years) Headache Dose 1: 42% (≤55 years); 25% (>55 years) Dose 2: 52% (≤55 years); 39% (>55 years) |
mRNA-1273 (Moderna)43 | Phase 3, OB, PC, R N = 30,420 Age: ≥18 years (mean 51.4 years, range 18–95 years) Males: 52.7% | Dose 1: 83.7% (all); 86.9% (<65 years); 74.0% (≥65 years) Dose 2: 88.2% (all); 89.9% (<65 years); 83.2% (≥65 years) | Fatigue Dose 1: 37.2% (all); 38.4% (<65 years); 33.3% (≥65 years) Dose 2: 65.3% (all); 67.6% (<65 years); 58.3% (≥65 years) Headache Dose 1: 32.7% (all); 35.3% (<65 years); 24.5% (≥65 years) Dose 2: 58.6% (all); 62.8% (<65 years); 46.2% (≥65 years) |
Adenovirus-based | |||
AZD1222 (Oxford/AZ)47 | Phase 2, R, C N = 420 Age: ≥18 years (n = 100 aged 18–55, n = 120 aged 56–69, and n = 200 aged ≥70) Males: 50%* | Dose 1: 61% (18–55 years); 43% (56–69 years); 20% (≥70 years) Dose 2: 49% (18–55 years); 34% (56–69 years); 10% (≥70 years) | Fatigue Dose 1: 76% (18–55 years); 50% (56–69 years); 41% (≥70 years) Dose 2: 55% (18–55 years); 41% (56–69 years); 33% (≥70 years) Headache Dose 1: 65% (18–55 years); 50% (56–69 years); 41% (≥70 years) Dose 2: 31% (18–55 years); 34% (56–69 years); 20% (≥70 years) |
Ad26.COV2.S (Janssen/J&J)50 | Phase 3, DB, PC, R N = 44,325 Age: ≥18 years (median 52 years, range 18–100 years) Males: 54.9% | 48.6% (all); 58.6% (18–59 years); 33.3% (≥60 years) | Fatigue 38.2% (all); 43.8% (18–59 years); 29.7% (≥60 years) Headache 38.9% (all); 44.4% (18–59 years); 30.4% (≥60 years) |
Inactivated virus | |||
BBIBP-CorV (Sinopharm)52 | Phase 2, R, DB, PC N = 448 Age: 18–59 years (mean 41.7 years, SD 9.9 years) Males: 45% | 16%‡ | Fatigue: 3%‡ Headache: 1%‡ |
CoronaVac (Sinovac Biotech)53 | Phase 2, R, DB, PC N = 600 Age: 18–59 years (mean 42 years) Males: N/A# | Doses on Day 0 and 14: Dose 1: 9.2% (3 µg), 16.7% (6 µg) Dose 2: 13.3% (3 µg), 11.8% (6 µg) Doses on Day 0 and 28: Dose 1: 7.5% (3 µg), 10.0% (6 µg) Dose 2: 2.6% (3 µg), 5.9% (6 µg) | Fatigue Doses on Day 0 and 14: Dose 1: 1.7% (3 µg), 5.0% (6 µg) Dose 2: 1.7% (3 µg), 1.7% (6 µg) Doses on Day 0 and 28: Dose 1: 8.3% (3 µg), 1.7% (6 µg) Dose 2: 2.6% (3 µg), 0.9% (6 µg) Headache Doses on Day 0 and 14: Dose 1: 0.8% (3 µg), 0.8% (6 µg) Dose 2: 0.8% (3 µg), 2.5% (6 µg) Doses on Day 0 and 28: Dose 1: 2.5% (3 µg), 0.8% (6 µg) Dose 2: 1.7% (3 µg), 0.0% (6 µg) |
CoronaVac (Sinovac Biotech)54 | Phase 1/2, R, DB, PC N = 349 (Phase 2) Age: ≥60 years (mean 66.6 years, SD 4.7 years) Males: 48% | Dose 1: 2% (1.5 µg), 8% (3 µg), 5.1% (6 µg) Dose 2: 9.1% (1.5 µg), 7% (3 µg), 5.1% (6 µg) Doses were administered on Day 0 and 28 | Fatigue Dose 1: 3% (1.5 µg), 3% (3 µg), 2% (6 µg) Dose 2: 1% (1.5 µg), 0 (3 µg), 1% (6 µg) Headache Dose 1: 0 (1.5 µg), 0 (3 µg), 2% (6 µg) Dose 2: 0 (1.5 µg), 0 (3 µg), 0 (6 µg) |
